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ABSTRACT
Background    In recent years, neoadjuvant chemothera-
py (NAC) is often performed for patients with unresect-
able breast carcinoma or without indication of breast 
conserving therapy. However, it is currently difficult to 
predict response to NAC with diagnostic imaging of 
breast carcinoma. In this study, we investigated imaging 
findings that could serve as a predictor of the response 
to NAC for patients with invasive breast carcinoma.
Methods    Twenty-six patients with invasive breast car-
cinoma who received NAC at the Division of Breast and 
Endocrine Surgery of Tottori University Hospital be-
tween January 2010 and May 2014 were retrospectively 
investigated. Their imaging findings from mammograms 
and ultrasonograms were reviewed. The association 
between findings on mammograms and ultrasonograms 
captured before NAC and response to treatment after 
NAC was examined.
Results    Of the 26 patients with invasive breast car-
cinoma, 19 (73%) responded well to treatment and 7 
(27%) did not. Most notably, all 10 patients who had 
microcalcifications on mammogram responded well to 
treatment (53% of responders), and all patients who did 
not respond to treatment had no microcalcifications (P < 
0.05). Of these 10 patients, 9 (90%) had microcalcifica-
tions of comedo type and one (10%) had non comedo 
type. As a distribution, 8 of the 10 (80%) had a clustered 
type of microcalcifications and the remaining 2 (20%) 
had a segmental type of them.
Conclusion     Microcalcifications of tumor observed 
in mammogram (particularly comedo type) could be a 
predictor of response to NAC for patients with invasive 
breast carcinoma.
Key words     breast carcinoma; microcalcification; neo-
adjuvant chemotherapy
Neoadjuvant chemotherapy (NAC) is used to treat inva-
sive breast carcinoma when the carcinoma is unresect-
able or when breast-conserving surgery is not indicated. 
Some advantages of NAC include downstaging due 
to tumor shrinkage and improved survival in patients 
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Abbreviations: CT, computed tomography; DTX, docetaxel hydrate; 
ER, estrogen receptor; FEC, (F: fluorouracil, E: epirubicin hydro-
chloride, C: cyclophosphamide); HER2, human epidermal growth 
factor receptor type2; NAC, neoadjuvant chemotherapy; pCR, 
pathological complete response; PD, progressive disease; PR, partial 
response; RECIST, Response Evaluation Criteria in Solid Tumors; 
SD, stable disease
showing a pathological complete response (pCR).1–4 
However, changes in medications or adjustments to the 
course of treatment (e.g., surgery) could be necessary if 
a patient does not respond.
 In this study, we investigated imaging findings of 
invasive breast carcinoma that could serve as a predictor 
of response to NAC with the aim of reducing the fre-
quency of unnecessary treatment.
 
SUBJECTS AND METHODS
Twenty-six patients with invasive breast carcinoma who 
received NAC at the Division of Breast and Endocrine 
Surgery of Tottori University Hospital between January 
2010 and May 2014 were retrospectively investigated. 
Their imaging findings from mammograms and ultra-
sonograms were reviewed individually without patients 
information by two medical breast cancer specialists 
who had over 25 years experiences in breast examina-
tions. When mutual evaluation of findings was not 
matched, consensuses were got in each other. The asso-
ciation between findings on mammograms [tumor (size, 
shape, and border/margin), microcalcifications (mor-
phology and distribution)] and ultrasonograms [tumor 
size, shape, border area, halo, internal echo, posterior 
echo, and high echogenic foci] before NAC and response 
to NAC was assessed. 
 Of the 26 patients, 14 received DTX (docetaxel hy-
drate) followed by FEC (F: fluorouracil, E: epirubicin 
hydrochloride, C: cyclophosphamide), 11 received DTX 
plus trastuzumab followed FEC, and one received trastu-
zumab alone. The typical number of cycles was 4 of 
FEC and 4 of DTX. Response to NAC was determined 
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according to the Response Evaluation Criteria in Solid 
Tumors (RECIST)5 using contrast computed tomogra-
phy (CT), and well response was defined as either a CR 
or partial response (PR). All patients besides one patient 
who had progressive disease (PD) after NAC underwent 
mastectomy or breast-conserving surgery. Fischer’s 
exact test was used for statistical analysis and P < 0.05 
was considered significant. This study was approved by 
the ethics review board of Tottori University Faculty of 
Medicine. 
RESULTS
All patients were women and mean age was 55 years 
(range: 27–70 years). Of the 26 patients, 19 (73%; CR: 6, 
PR: 13) responded well to treatment and 7 [27%; stable 
disease (SD): 6, PD: 1] did not. All 10 patients who had 
microcalcifications on mammogram responded well to 
treatment (53% of responders), and all patients who did 
not respond to treatment had no microcalcifications (P < 
0.05) (Fig. 1). Of these 10 patients with microcalcifica-
Fig. 1. Microcalcifications and response to treatment. All breast 
carcinomas with microcalcifications responded well to treatment 
(P < 0.05).
tions on mammogram, 9 (90%) had microcalcifications 
of comedo type and one (10%) had non comedo type (Fig. 
2). Eight of the 10 (80%) had a clustered distribution 
of microcalcifications and the remaining 2 (20%) had 
a segmental distribution of them (Fig. 3). Additionally, 
7 of the 10 patients with microcalcifications, including 
6 of the 9 patients with microcalcifications of comedo 
type, had overexpressed human epidermal growth fac-
tor receptor type2 (HER2). But there was no association 
between microcalcifications and HER2 overexpression 
(Table 1). When the association between response to 
treatment and the regimen of NAC was examined, it was 
found that all 11 patients who received trastuzumab in 
combination therapy (all of them had HER2 overexpres-
sion) responded well to treatment. Furthermore, 7 of the 
11 had microcalcifications and 6 of the 7 with microcal-
cifications were comedo type. The patient who received 
trastuzumab alone did not respond well to treatment. No 
other findings on mammograms or ultrasonograms were 
associated with response to treatment.
Fig. 2. Type of microcalcifications. Most microcalcifications were 
comedo type.
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Table 1. Microcalcifications and HER2 overexpression
Microcalcifications (+) Microcalcifications (−) Total
HER2 (+) 7 5 12
HER2 (−) 3 11 14
Total 10 16 26
There was no association between microcalcifications and HER2 overexpression (P = 0.105).
Values within table indicate number of patients.
HER2, human epidermal growth factor receptor type2. 
value in breast carcinoma with microcalcifications of 
comedo type.11 As to association between Ki-67 and 
chemotherapy, Criscitiello et al. reported that the addi-
tion of chemotherapy to endocrine therapy is useful for 
estrogen receptor (ER) positive, node positive breast car-
cinoma with high Ki-67 value.12 And, Petit et al. found 
that breast carcinoma patients with low ER expression 
and high Ki-67, responded well to NAC.13 Moreover, 
several studies have shown that patients with high Ki-67 
are more likely to show a pathological CR.14, 15
 The above findings demonstrate that microcalcifica-
tions of comedo type reflect the proliferative potential of 
breast carcinoma. Additionally, the fact that NAC is ef-
fective against breast carcinomas with highly prolifera-
tive activity, may explain that breast carcinoma patients 
with microcalcifications on mammogram responded 
well to treatment in this study.
 In conclusion, the present study suggests that mi-
crocalcifications on mammogram (particularly comedo 
type) could be a predictor of response to NAC for pa-
tients with invasive breast carcinoma.
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